Robert A. Wermers, MD is an Associate Professor of Medicine at the Mayo Clinic. Dr. Wermers studies clinical and epidemiologic aspects of metabolic bone disease. This includes analysis of five decades of the epidemiology of primary hyperparathyroidism in Rochester, Minnesota. He has also reviewed epidemiologic aspects of thiazide-associated hyperparathyroidism and Paget's disease of bone in Rochester.
Dr. Wermers is also interested in clinic research in the field of metabolic bone disease, with multiple projects in several different areas, including evaluating the effect of parathyroidectomy on depression and bone mineral density in primary hyperparathyroidism, clinical features of adult hypophosphatasia, decision aids in the treatment of osteoporosis, combination therapy for the treatment of osteoporosis, and fluoride-related bone disease.
Dr. Wermers would like to expand the understanding of optimal clinical management of primary hyperparathyroidism. He also hopes to better elucidate the natural history of this common disease. Little is known about the natural history and clinical management of thiazide-associated hypercalcemia. Hence, Dr. Wermers wants to provide guidance on how best to treat this clinical disorder. He also wants to expand the clinical knowledge of less common, but highly impactful, metabolic bone diseases, such as CYP24A1 mutations, voriconazole-related fluoride excess and hypophosphatasia, which are currently in an early stage of investigation.